• OPEN AN ACCOUNT
A+| A| A-|
Indian Indices
Sensex
77,664.00 -852.49
( -1.09%)
Global Indices
Nasdaq
49,509.71 339.32
(0.69%)
Dow Jones
7,158.76 73.75
(1.04%)
Hang Seng
59,249.10 -336.76
(-0.57%)
Nikkei 225
10,468.22 -8.24
(-0.08%)
Forex
USD-INR
93.44 0.45
(0.48%)
EUR-INR
109.88 0.43
(0.39%)
GBP-INR
126.24 0.55
(0.44%)
JPY-INR
0.59 0.00
(0.27%)

EQUITY - MARKET SCREENER

Vivimed Labs Ltd
Industry :  Pharmaceuticals - Indian - Bulk Drugs & Formln
BSE Code
ISIN Demat
Book Value()
532660
INE526G01021
0.9167078
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
VIVIMEDLAB
0
57.38
EPS(TTM)
Face Value()
Div & Yield %
0
2
0
 

Maruti Suzuki reports 12% YoY sales growth in January 2026
Feb 02,2026
Domestic passenger vehicle (PV) sales stood at 174,529 units, marginally higher by 0.5% YoY, while sales of light commercial vehicles (LCVs) declined 7.8% YoY to 3,771 units during the month.

While the company’s total domestic sales (PV+LCV+OEM) rose 0.4% YoY to 185,943 units, export sales, however, surged 88.3% YoY to 51,020 units, marking an all-time monthly high.

For the period from April to January of FY26, the company has registered total sales of 1,983,467 units, up 7.7% YoY.

Maruti Suzuki India is engaged in the manufacture, purchase, and sale of motor vehicles, components, and spare parts (automobiles).

The company reported a 4.08% YoY increase in net profit to Rs 3,879.1 crore in Q3 FY26, compared with Rs 3,726.9 crore in Q3 FY25, while revenue from operations rose 28.74% YoY to Rs 49,904.1 crore.

Shares of Maruti Suzuki India rose 0.31% to Rs 14,244.90 on the BSE.